 To assess the maximum tolerated dose and overall safety and tolerability of sunitinib SU011248 administered in combination with gefitinib Iressa for the treatment of patients with metastatic renal cell carcinoma Phase 1. To assess antitumor activity of the combination of gefitinib and sunitinib Phase 2. 